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THIS study  intended  to  characterize  pharmacolog-
ically the mediator(s)  released  in the inflammation
induced  by  Soluble  Egg  Antigen  (SEA),  the  main
antigen released from eggs of Schistosoma mansoni,
in  rat  hindpaws.  A  single  intraplantar  injection  of
0.1–100 m g SEA at day zero induced a dose-dependent
increase in the volume of rat hindpaws characterizing
an  oedema  of  quick  onset  (within  15 min)  and
4 h-duration,  which  was  confirmed  by  histopatho-
logical analysis of the paws. A second injection of SEA
in the same paw (1–10 m g) 28 days later induced an
increased dose-dependent  oedematogenic  response.
The  early  oedematogenic  response  following  SEA
sensitization was derived from serotonin release and
interleukin-1 (IL-1), since treatment with either pizo-
tifen  or  an  antibody  against  IL-1,  reduced  the
response  by  60%  and  48%,  respectively.  The
increased oedematogenic response derived from SEA-
challenge  (10 m g)  of  rat  paws  derived  from  a  local
rather  than  systemic  reaction,  since  it  was  not
observed if the sensitization was in the contralateral
paw or the peritoneal cavity of the animals. Chronic
treatment  with  inhibitors  of  IL-2  synthesis/release
such  as  cyclosporin  or  dexamethasone  during  the
sensitization  phase  reduced  the  oedematogenic
response  due  to  SEA  challenge  by  51%  and  55%,
respectively. These data suggested that SEA-challenge
was immune-derived and dependent of IL-2 release. It
is discussed the association between cytokine release
and the resistance of rats to S. mansoni infection.
Key  words:  Schistosoma  mansoni,  Soluble  Egg Antigen
(SEA), Oedema, Serotonin, IL-1, IL-2, Cytokines
Introduction
Schistosomiasis, a chronic disease caused by infection
with  the  helminths  Schistosoma  mansoni,  Schisto-
soma  haematobium or  Schistosoma  japonicum,
presents a worldwide distribution and a varied degree
of severity.
1,2 S. mansoni is the predominant schisto-
some found in the Western world, apart from being
also  found  in  the  Middle  East  and  Africa,
2 which
induces a disease of moderate severity.
1
The  severity  of  schistosomiasis  relies  on  the
modulation  of  a  tissue  granulomatous  response
derived from the release of adult  worm antigens in
the  host  circulation  associated  with  the  slow
release of larval-egg cross-reactive antigens and sub-
sequently  by  egg-specific  antigens.
3,4 Soluble  Egg
Antigen  or  SEA  is  the  term  used  to  collectively
characterize  the  antigens  released  by  the  eggs
deposited by Schistosoma worms in the tissues and
is  composed  by  nine  fractions  of  proteins  with
varied  profile  of  immunogenicity.
4 The  principal
source of SEA  is the skin  of the embryo inside the
egg,  which  at  this  stage,  is  called  miracidium,
although  it  can  also  be  released  from  the  adult
worm  and  from cercariae.
3
The  host  granulomatous  response  to  S. mansoni
infection in sensitive species can be down-modulated
by enhanced T-suppressor cell-activity and diminished
CD4
+ T-lymphocyte  responsiveness  expressed  by
reduction  in  cytokine  release  and  lymphocyte  pro-
liferation.
5,6 Curiously, it has been demonstrated that
rats  are  resistant
7 or ‘non-permissible’
8 hosts  to  S.
mansoni infection.
In  past  years,  SEA  has  been  used  as  a  tool  to
study  immune-mediated  inflammatory  reactions
9
and  the  development  of  a  vaccine  against  schisto-
somiasis  mansoni  has  progressively  been
appreciated.
10–13
In the present study, we used a preparation of eggs
and  SEA from  S. mansoni injected intraplantarly  to
evaluate the mechanism of inflammation induced in
rat paws.
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Animals
Holtzman  female  rats  weighing  150–200 g  were
housed  at  25±3°C,  under  a  12 h  light/dark  cycle
(lights on 07:00h) with water and food ad libitum.
Male albino Swiss mice were used as a source of S.
mansoni eggs.  In  all  experiments,  the  number  of
animals used varied between 3 and 16.
Obtaining S. mansoni eggs and SEA
S. mansoni eggs were obtained from the liver of mice
infected with cercariae 8 weeks before, as previously
described.
14 The  purified  eggs  were  fragmented  in
tissue grinders using phosphate-buffered saline (PBS,
0.01 M,  pH=7.4).  This  procedure  determined  mir-
acidium  release  thus  facilitating  the  obtainment  of
SEA (Schistosoma mansoni Soluble Egg Antigen). The
crude material was centrifuged at 100 000 g for 2 h at
4°C. Various supernatants (SEA) were combined and
evaluated for protein content by the Lowry method
15
and kept at –20°C until assayed. Only one pool of SEA
has been used throughout the present studies.
Oedema measurements
Measurements of the volume of rat paws were carried
out using a hydroplethysmometer Ugo Basile (model
7150) before and after an intraplantar (i.pl.) injection
of various doses of a suspension of S. mansoni eggs
(2000  eggs/ml  in  PBS)  or  SEA  diluted  in  0.1 ml  of
physiological saline at zero time. A second injection of
SEA (in  0.1 ml  sterile  physiological  saline)  was  also
given  28  days  later  in  the  same  paw  whenever
otherwise stated. The contralateral paw received the
same  volume  of  sterile  physiological  saline.  Results
are presented as the mean difference between volu-
mes (D V, m l) obtained from the paws injected with
eggs or SEA and those injected with saline ± standard
error  of  the  mean  (SEM)  in  each  group.  In  all  the
experiments the measurements were obtained at 5,
15,  30,  60,  120,  240 min  and  24h  following  intra-
plantar (i.pl.) injections (n=4–13/group).
Selection of an inhibitory dose of an antibody
against interleukin 1b (IL-1b )
To assess an  inhibitory  dose  of an  antibody against
human  IL-1b , two dilutions (1/20–1/200)  of a  com-
mercial  preparation  of an  antibody  injected by sub-
cutaneous  (s.c.)  route  were  tested  in  an  assay  of
leukocyte migration induced by intraperitoneal (i.p.)
injection of human IL-1b in rats. The technique used
to  count  leukocytes  was  described  elsewhere.
16 In
the assay, it has been shown that 1.45 3 10
–10 M of
human  IL-1b increased  the rat  peritoneal  leukocyte
number  by  29%  (P <  0.05, Anova  t-test,  Fig.  1). A
dilution of 1/20 of the antibody reduced the leuko-
cyte counts increased by human IL-1b to the level of
control animals (> 99% reduction, Fig. 1), whereas a
1/200  dilution  of the antibody  did  not  significantly
alter human IL-1b -induced effect. The 1/20 dilution of
the antibody was used in rat paws injected with SEA
for further studies.
Experimental protocols
Four sets of experiments were established to evaluate
the participation  of known mediators release in the
inflammation  induced by eggs or SEA from S. man-
soni in rat paws. All antagonists used inhibited at least
40% of the maximum oedematogenic effect of their
respective  agonists  injected  into  the  rat  paws  and
tested  in  parallel  assays.  In  the  case  of  HOE  140
(bradykinin  antagonist),  L-NAME  (nitric  oxide  syn-
thase  inhibitor),  indomethacin  and  dexamethasone
(non-steroidal  and steroidal anti-inflammatory drugs,
respectively)  the  agonist  used  was  carrageenin
(250 m g/site).  For  pizotifen,  pyrilamine  and  SR
140333
17 a dose of 5 m g of serotonin (5-HT), 50 m g of
histamine (H) and 50 m g of Substance P (SP), respec-
tively,  were  used per  site. In  the  first  set, effective
doses of pizotifen, pyrilamine, indomethacin or intra-
muscular (i.m.) dexamethasone were acutely admin-
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FIG. 1. Inhibition of human interleukin-1b -induced leukocyte
recruitment  to  peritoneal  cavity  of  rats  by  subcutaneous
injection of an antibody  against human  IL-1b . Cell counts
were  performed  4h  after  i.p.  injections.  Control  bar  (C)
represents counts of leukocytes from animals injected i.p.
with 1ml of sterile physiological  saline. Sterile IL-1b was
injected i.p. at 1.45 3 10–10 M. Dilutions of the antibody were
also  made  in  physiological  saline.  *Represents  P <  0.05
(Anova  t-test)  compared  with  control  animals
(n=5–7).**Represents  P <  0.01  from  comparison  with  IL-
1b -injected animals (Anova t-test).istered  30 min  before  i.pl.  injection  of  SEA  (time
zero), as shown in a previous work.
18 The compound
SR 140333  was i.p. injected 15 min before SEA. The
increase  in  paw volume was  obtained as  described
above during sensitization  and  challenge phases. In
the second set of experiments, pizotifen, dexametha-
sone and indomethacin were acutely administered by
i.pl.  route  30 min  before  challenge  with  SEA
(10 m g/paw).  In  the  third  set,  dexamethasone  and
cyclosporin  A  (an  immunosuppressive  drug)  were
chronically administered by i.m. route from day 0 to
day  14  following SEA sensitization  (10 m g/paw) and
oedema measurements were obtained after SEA chal-
lenge  (10 m g/paw).  Finally,  a  1/20  dilution  of  an
antibody against human IL-1b was also administered
by  i.pl.  route  15min  before  SEA  sensitization
(10 m g/paw) and the resultant effect on SEA sensitiza-
tion (10 m g/paw) was also evaluated. The dose of all
drugs  used  were  depicted  in  the  tables  or  figure
legends.
Histopathological studies
Rats injected intraplantarly with SEA were sacrificed
with ether in different time points and the hindpaws
immediately cut at the tibial-tarsic joint. A square of
1 cm was made with  a sharp scalpel in the pads of
each paw (control and SEA-injected) around the site
of injection to permit easy fixation of the tissue which
was  then  quickly  immersed  in  Bouin  fixative  over-
night. The following day Bouin solution was exchan-
ged by  ethanol  70% and the paws were left in  this
solution until embedded in parafin and cut in sections
of 5 m m. Slides containing the sections of paw tissue
stained  by  haematoxilin-eosin  were  evaluated  for
oedema and cell migration in various time points by
optical mycroscopy (1000-fold amplification).
Drugs
Salts  used  in  the  present  work  and  the  following
chemicals  were  purchased  from  Sigma:  pyrilamine,
indomethacin, L-NAME, dexamethasone, human inter-
leukin 1b and anti-human IL-1b (developed in rabbit,
IgG fraction). Pizotifen and cyclosporin A, SR140333
(a NK1-receptor antagonist) and HOE 140 were kindly
donated  by  Fl´ avio  J.  R.  de Aguiar  (Sandoz,  Brazil),
Xavier Emonds-Alt (Sanofi, Montpellier) and Dr Mauro
M.  Teixeira  (Departamento  de  Farmacologia,  ICB,
UFMG), respectively.
Statistical analysis
The  increase  in  volume  of  rat  paws  or  peritoneal
cellular counts (mean ± standard error of the mean)
following administration  of the agonists whether or
not under different treatments were compared with a
control using Student’s t-test for single comparisons
FIG. 2. Intraplantar injection of SEA (S. mansoni Soluble Egg
Antigen)  in  rats  reproduces  the  oedematogenic  response
induced  by  challenge  of  sensitized  rats  with  S.  mansoni
eggs. In (A), it is shown the oedematogenic effect induced by
different doses of eggs in sensitization (n=4–6). In (B), the
oedematogenic effect induced by a second injection of eggs
in rat paws is shown (n=4–6). In (C), 1 or 10m g/site of SEA
were  injected  i.pl. instead  the  eggs  in challenge  (n=3–6).
Measurements were obtained in a hydroplethysmother (Ugo
Basile) at zero, 15, 30, 60, 120 and 240min following i.pl.
administration of the 40 or 200 eggs  in 0.1ml of physio-
logical saline/site [E].
Inflammation induced by SEA in rat paws
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developed  by  the  SigmaStat  software,  accepting  a
value as statistical significant when P<0.05.
Results
Intraplantar administration of S. mansoni eggs (40 or
200 eggs/0.1 ml) induced a dose-dependent increase
in rat paw volume thus characterizing oedema forma-
tion which was maximal at 120 min following admin-
istration  (0.27  ±  0.03 ml),  remained  significantly
elevated  by  240 min  (0.25  ±  0.02 ml;  Fig.  2A)  and
subsided  24 h  later  (data  not  shown).  A  second
injection of 200 eggs in the same paw 28 days later
induced  an  increased  oedematogenic  response  at
15 min following injection  (0.75 ± 0.15 ml; Fig. 2B),
which was reproduced if 10 m g SEA was used instead
of S. mansoni eggs in the challenge (0.89 ± 0.10; Fig.
2C).  Sensitization  of  rats  with  SEA  also  induced
oedema  which  was  maximal  15–30 min  following
injection  and lasted for 4 h, depending on the dose
used (Fig. 3). No oedema was detected following i.pl.
injection  of  SEA  after  24 h  (Fig.  3).  However,  the
oedematogenic  activity  of  SEA  was  progressively
decreased  during  the  development  of  the  experi-
ments. Such variation is illustrated in the column of
control results in Table 1. The acute oedema following
SEA sensitization of rats was 60% reduced by previous
systemic  administration  of  pizotifen  (2 mg/kg) s.c.,
but it was not modified by effective anti-oedemagenic
doses of pyrilamine (2 mg/kg)s.c., SR 140333 (1 mg/
kg)  i.p.,  indomethacin  (2mg/kg) s.c.,  L-NAME
(0.5 mg/kg) s.c.,  or  dexamethasone  (1mg/kg)  i.m.
(Table 1). In addition, the increased oedematogenic
effect presented by the latter animals to SEA challenge
was  not  modified  28  days  later  (data  not  shown).
Challenge of animals with 1 or 10 m g SEA induced a
dose-dependent  increase  of  the  oedematogenic
response in animals previously sensitized with 10 m g
SEA (Table 2). However, this increase was not seen if
C. M. F. Pacheco et al.
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FIG. 3. Dose–response (oedema) curve induced by admin-
istration of S. mansoni Soluble  Egg  Antigen  (SEA) in rat
paws. Various doses (1, 10, 50 and 100m g/site) of the antigen
were  diluted  in  0.1ml  physiological  saline  and  injected
intraplantarly in rat hindpaws. Measurements were obtained
in a hydroplethysmother (Ugo Basile) at zero, 15, 30, 60, 120,
240min  and  24h  following  administration  of  the  antigen
(n=6–15).  Statistical  significance  is  indicated  by  *P<0.05
(Anova t-test).
Table 1. Anti-oedematogenic effect of known inhibitors of the syntesis of inflammatory mediators and antagonists on the
oedema induced by SEA following sensitization of rat paws
Drug (mg/kg); route Receptor/mechanism
involved
Agonist Oedema on sensitizationa (ml)
Control Treated
Pizotifen (2);s.c. 5-HT2 Serotonin 0.47 ± 0.04 0.19 ± 0.05*
Pyrilamine (2);s.c. H1 Histamine 0.30 ± 0.05 0.31 ± 0.05
SR 140333 (1); i.p. NK1 Substance P 0.37 ± 0.04 0.35 ± 0.03
Indomethacin (2);s.c. Cyclooxygenase inhibitor Carrageenin 0.29 ± 0.02 0.26 ± 0.06
Dexamethasone (1); i.m. Phospholipase inhibitor Carrageenin 0.30 ± 0.09 0.20 ± 0.07
L-Name (0.5);s.c. Nitric oxide synthase inhibitor Carrageenin 0.36 ± 0.06 0.32 ± 0.02
aValues were recorded at maximal oedematogenic effect (mean ± SEM). Significance of changes are indicated (*P < 0.05, Anova t-test).
Table 2. Increase of the oedematogenic effect induced by
different doses of SEA in challenge of rat paws sensitized 28
days before
SEA dose on sensitization
(m g/site)
Oedemaa (ml)
1m g 10m g
Control 0.08 ± 0.02 0.32 ± 0.05
1 0.06 ± 0.01 0.39 ± 0.07
10 0.38 ± 0.10 0.57 ± 0.01*
50 0.40 ± 0.10 0.40 ± 0.08
100 ND 0.50 ± 0.05
aValues were recorded  at maximal oedematogenic  effect  (mean ±
SEM) 28 days later (challenge). Significance of changes is indicated (*
P < 0.05, Anova t-test) and determined vs. control for the same dose
of SEA.higher  doses  of  SEA  were  used  in  sensitization,  as
shown  in Table 2. This secondary oedema was also
57%  reduced by  acute  local  treatment  of  the  paws
with  pizotifen  (100 m g/site), but  not with  the same
dose  of  indomethacin  or  dexamethasone  (Table  3).
The  dose  of  10 m g/paw  of  SEA  in  challenge  was
chosen as standard for posterior studies. Interestingly,
if the sensitization with 10 m g SEA was done in the
contralateral  paw  (clp)  or  intraperitoneally  (i.p.)  in
the animals 28 days before, no increase was observed
in challenge (oedema following clp: 0.30 ± 0.04; i.p. =
0.30  ±  0.04,  respectively).  In  addition,  this  lack  of
effect on  challenge to SEA  in  other location  of the
body was independent of the dose of the antigen used
in  sensitization  (data  not  shown).  Histopathological
studies confirmed the early oedema (15 min) induced
by  SEA,  showing  vasodilation  of  the  pad  micro-
vasculature, separation of collagen fibres and oedema
fluid being drained by lymphatic vessels at this time
point  (data  not  shown).  Recruitment  of  a  mixed
population  of  leukocytes  (poly  and  mononuclear
cells)  was  observed  around  2 h  of  the  injections,
being  increasingly  substituted by  mononuclear cells
at 24 h following injection. Chronic treatment of rats
with i.m. 0.1mg/kg/day dexamethasone or 5 mg/kg/
day cyclosporin from day 0 to day 14 of SEA-sensitized
animals reduced  by  51%  and  54%,  respectively,  the
oedematogenic  response  on  SEA  challenge,  i.e.  14
days  later  (Table  4).  Observation  of  the  animals
treated with such doses on sensitization (day 0) did
not  change  the  immediate  followed  oedematogenic
response  (data  not  shown). Acute  treatment  of  rat
paws with an antibody anti-human IL-1b reduced by
48% the oedematogenic response induced by SEA on
sensitization of rat paws (Fig. 4).
Discussion
Development  of  schistosomiasis,  a  parasitic  disease
due  to  the  Trematoda  Schistosoma  mansoni,  is
highly  dependent  on  the  antigen  burden  derived
either from the adult  worms present  in the circula-
tion or from the eggs usually deposited in the liver
of the host.
8 The substances extracted from the eggs
of S. mansoni are collectively named by SEA
4 which
seems  to  be  the  main  inducer  of  a  modulated
response  in  the  chronic  phase  (granulomatous)  of
the disease,
5,19 In addition, SEA has been used as a
Inflammation induced by SEA in rat paws
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Table 3. Local effect of pizotifen, indomethacin and dexamethasone on oedema induced by SEA challenge of rat paws
Drug Receptor/mechanism
involved
Agonist Oedema in challengea (ml)
Control Treated
Pizotifen 5-HT2 Serotonin 0.41 ± 0.03 0.18 ± 0.02*
Indomethacin Cyclooxygenase inhibitor Carrageenin 0.30 ± 0.03 0.32 ± 0.03
Dexamethasone Phospholipase A2 inhibitor Carrageenin 0.32 ± 0.04 0.21 ± 0.05
aValues were recorded at maximal oedematogenic effect (mean ± SEM). Significance of changes is indicated (* P< 0.05, Anova t-test). Drugs
(100m g/site) were administered intraplantarly 30min before SEA.
Table  4.  Effect  of  chronic  treatment  with  systemic  dex-
amethasone and cyclosporin on the oedematogenic effect of
SEA on challenge of rat paws
Drug (mg/kg/day) Oedemaa (ml)
Control Treated
%  Inhibition
Dexamethasone (0.1) 0.39 ± 0.03 0.20 ± 0.02* 51
Cyclosporine (5) 0.62 ± 0.10 0.34 ± 0.05* 54
aValues were recorded  at maximal oedematogenic  effect  (mean ±
SEM). Drugs were administered at the indicated doses from day 0 to
14 of sensitization. *P < 0.05 (Anova t-test).
FIG.  4.  Reduction  of  oedematogenic  response  to  SEA
sensitization by  an  antibody  anti-IL-1b . The  antibody  was
injecteds.c. 30min before injection of the antigen. Measure-
ments were obtained in a hydroplethysmother (Ugo Basile)
at zero, 15, 30, 60, 120, 240min and 24h following admin-
istration  of  the  antigen  (n=4–5). Statistical  significance is
indicated by *P<0.05 (Anova t-test).tool to understand the mechanisms of disease involv-
ing the immune system in experimental studies.
9 In
the present  work, we have shown that S. mansoni
eggs induced inflammation in rat pads, and that SEA
reproduced  the  oedematogenic  effect  of  the  injec-
tion of S. mansoni eggs, thus demonstrating that the
main oedematogenic effect derived from eggs is due
to  SEA. We  have  also  shown  that  SEA  induced  an
increased  oedematogenic  response  on  a  second
administration  to  the  animals  (challenge),  after  a
period of 28 days, suggesting the involvement of the
immune  system  in  the latter response. A  surprising
observation,  however,  was  that  the  involvement  of
the immune system was local rather than systemic,
since the increased effect on SEA challenge was only
observed  if  the  antigen  were  injected  in  the  same
location  of the  sensitization,  i.e.  into  the  ipsilateral
paw. This  result  suggested  that  (1)  SEA  is  a  weak
antigen,  or  conversely,  rats  restrain  very  effectively
the immune response to it, and (2) SEA is very easily
cleared  out  of  the  animal  bodies,  unless  it  is  con-
tinuously  delivered  from  the  eggs  into  the  circula-
tion, as it happens during the course of the disease
in  sensitive  species.  Irrespective  of  the  increase  in
polymorphonuclear  and  mononuclear  cells  (macro-
phages  and  lymphocytes)  into  the  rat  paws,  as
shown  by  histopathological  studies,  the  cellular
source  of  the ‘local’  immune  response  to  SEA  was
not  addressed  in  the  present  work.  It  was  estab-
lished at least 30 years ago by Parrat and West
20 that
serotonin  (5-HT) was the main inflammatory media-
tor  released  in  rat  pads.  In  fact,  here  we  demon-
strated that serotonin accounted for 60% and 57% of
the oedematogenic response to SEA in  sensitization
and challenge of rat paws, respectively, since pizoti-
fen, a 5-HT2 antagonist,
21 blocked both systemically
and locally the response. The release of other vasoac-
tive  substances  by  SEA,  such  as  bradykinin,  hista-
mine,  substance  P,  prostaglandins,  leukotrienes,
nitric  oxide  or  platelet  activating  factor  (PAF)  was
discarded,  since  previous  acute  administration  of
their specific antagonists or synthesis inhibitors have
not modified the oedematogenic response observed
following SEA sensitization. Therefore, it was reason-
able to suppose that the early serotonin release (by
15 min) induced vasodilation  and increased vascular
permeability  and  together  with  IL-1  (see  below)
contributed to the arrival of circulating leukocytes to
the paw  tissue shown  in  later times by  histopatho-
logical  studies. As  those  treatments  have  not  mod-
ified  the  oedematogenic  response  to  SEA  observed
on  challenge,  we  could  also  conclude  that  all  the
mediators  above  mentioned  were  not  important  in
the  pathophysiology  of  the  latter  response.  How-
ever, to our knowledge, it is the first demonstration
of  an  oedematogenic  effect  which  was  not  acutely
sensitive to the potent and efficacious steroidal anti-
inflammatory drug dexamethasone.
The participation of cytokines in the inflammatory
reaction due to SEA has been reported elsewhere.
4,12
Our data support the notion that the oedematogenic
effect induced by SEA in challenge is immune-derived
and  depends  on  the  release  of  cytokines  in  early
stages  of  the  reaction.  Basically,  three  arguments
favour our hypothesis: (1) a second injection  of the
antigen  induced  a  potentiated  oedematogenic
response; (2) drugs with immunosuppressive activity,
such as dexamethasone and cyclosporin  chronically
administered during the early stages of the reaction
greatly  reduced  (>  50%)  the  oedematogenic  effect
observed in  challenge; and  (3) an  antibody specific
against  IL-1b was effective  in  inhibiting  by  approx-
imately 50% the oedematogenic response to SEA. It
has  been  exhaustively  shown  that  dexamethasone
and  cyclosporin  are  able  to  inhibit  the  synthesis/
release  of  various  cytokines,  specially  interleukin-1
and  2,
22,23 the  mainstay  cytokines  involved  in  the
processing of immune responses.
24,25 As an antibody
specific  to  human  IL-1b significantly  blocked  the
oedema from 1 to 4 h of SEA sensitization of rat paws
by approximately 50%, it was concluded that IL-1 was
an important effector of the pathophysiology of this
oedema. In such case, IL-1 could effect this response
through recruitment and activation of leukocytes as
observed by the arrival  of these cells to paw tissue
from 2 h of SEA injections as confirmed by histopatho-
logical  studies. As  dexamethasone  treatment  of  rat
paws before SEA sensitization did not modify the early
oedematogenic response, it  was concluded that the
detected  reduction  of  the  oedema  by  the  antibody
during sensitization was, at least partially, due to its
binding to a preformed IL-1, eventually the biological/
immunological  analogous  of  IL-1b ,  IL-1a .
24 In  addi-
tion, IL-1 could be acting as an important effector of
other reactions of the immune response to SEA, such
as the activation and proliferation of T-cell lines, since
the  potentiated  oedematogenic  response  on  SEA
challenge was observed just in a narrow dose range
(1–10 m g). It might be emphasized that, although we
have used a human IL-1b and a antibody anti-human
IL-1b in  rats,  the  migration  of  leukocyte  and  its
blockade by the antibody were very consistent (29%
increase and > 99% inhibition, respectively), suggest-
ing that the site of interaction between IL-1 and the
host is relatively independent of its source and was
conserved in  the  evolution.  Our  data  have strongly
suggested  that  interleukin  2  is  involved  in  the
processing  of  the immune response  to  SEA  in  rats,
since early treatment of the sensitized animals with
cyclosporin, as with dexamethasone, greatly inhibited
the oedematogenic response on  challenge (> 50%).
Assuming that interleukin-2 is released by SEA, it is
tempting  to  speculate  that  the  immune  response
derived  from  SEA  injection  in  this  species  might
involve  predominantly  the  differentiation  of  the
lymphocytes  into  a Th1  subset,  rather  than  a Th2
C. M. F. Pacheco et al.
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26,27 If  it  is  so,  other  cytokines  such  as
interferon  gamma  and  interleukin  12  (IL-12)  may
eventually be detected in this model. Recent papers
have  shown  that  exogenous  IL-12  can  increase
vaccine-induced immunity to S. mansoni in mice.
11,28
Therefore, the association of IL-12 release with a very
effective immune response induced by IL-1 and IL-2,
as suggested by our results, could explain at least in
part, the resistance of rats to S. mansoni infection.
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